Cell therapy is the introduction of selected, and sometimes engineered, cells into a patient, harnessing the power of a patient’s immune system to combat their disease. The therapy may have wide applications as a cancer treatment, with the potential for cure in some patients.
Syncona has a world-leading cell therapy franchise developing products with the potential to treat patients across a range of diseases.
The Syncona team has established and built fully integrated companies with best-in-class manufacturing capabilities and world-leading management teams across innovative areas of cell therapy including: CAR-T, Tumour Infiltrating Lymphocytes, TCRs, T-Regulatory cells, iPSCs and macrophages.
Key facts
Unless stated all financials at 31 March 2023
£193m
Value of cell therapy portfolio
8
Number of clinical trials
7
Portfolio company Board seats
Our cell therapy portfolio companies
Latest cell therapy insights
The cell therapy pipeline
Best ideas
Pre-clinical
Clinical
Late Clinical
BLA
Our domain areas
Syncona has deep domain expertise across four key therapeutic areas.
